| human | Q5 |
| P496 | ORCID iD | 0000-0002-3149-7377 |
| P1053 | ResearcherID | K-4334-2013 |
| P735 | given name | Thomas | Q16428906 |
| Thomas | Q16428906 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q64447216 | 2019 ARIA Care pathways for allergen immunotherapy |
| Q58591901 | AAAAI Response to the EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria 2017 Revision |
| Q57066674 | ARIA Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology |
| Q96226501 | ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice |
| Q64360540 | ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD |
| Q64447220 | ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy” |
| Q96690282 | ARIA-EAACI statement on Asthma and COVID-19 (June 2, 2020) |
| Q102378292 | Airway relaxation mechanisms and structural basis of osthole for improving lung function in asthma |
| Q39365482 | Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision |
| Q52004908 | CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study |
| Q92562662 | Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from in vitro allergen-release data |
| Q41617712 | Degree of Neutrophil Chemotaxis Is Dependent upon the Chemoattractant and Barrier |
| Q72402542 | Demonstration that circulating human blood cells have no detectable alpha-adrenergic receptors by radioligand binding analysis |
| Q70160127 | Detection of beta-adrenergic receptors on rabbit mononuclear cells isolated free of significant contamination by other cell types |
| Q96138249 | EAACI Biologicals Guidelines - Recommendations for severe asthma |
| Q41525410 | Effects of neuropeptides on neutrophil migration through noncellular and endothelial barriers |
| Q89739188 | Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma |
| Q89605999 | Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma |
| Q90185425 | Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma |
| Q42360180 | Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review |
| Q37811349 | Future forms of immunotherapy |
| Q96644316 | Global implementation of the world health organization's international classification of diseases (ICD)-11: the allergic and hypersensitivity conditions model |
| Q46632369 | Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language |
| Q37795581 | Immunomodulators for Asthma |
| Q44330272 | Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: Evidence for opiate and nonopiate receptor participation |
| Q72007972 | Interleukin-8 mediates interleukin-1 alpha-induced neutrophil transcellular migration |
| Q38853489 | MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis |
| Q90807713 | Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence |
| Q26751386 | Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology |
| Q70219522 | Preparation of a human lung purified plasma membrane fraction: Confirmation by enzyme markers, electron microscopy, and histamine H1 receptor binding |
| Q38599656 | Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma |
| Q122983094 | Rhinitis associated with asthma is distinct from rhinitis alone: The |
| Q34090431 | Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. |
| Q55527154 | Sub-lingual immunotherapy: world allergy organization position paper 2009. |
| Q34400987 | The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation |
| Q48802333 | Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial |
| Q57313580 | Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma |
Search more.